Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).

Akshara Singareeka Raghavendra,Danielle N. Kwiatkowski,Senthil Damodaran,Nicole M. Kettner,David Ramirez,Dan S. Gombos,Kelly K. Hunt,Yu Shen,Khandan Keyomarsi,Debu Tripathy

Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).

2021

Akshara Singareeka Raghavendra
Danielle N. Kwiatkowski
Senthil Damodaran
Nicole M. Kettner
David Ramirez
Dan S. Gombos
Kelly K. Hunt
Yu Shen
Khandan Keyomarsi
Debu Tripathy

1067Background: Endocrine therapy with a CDK4/6 inhibitor is standard of care for patients (pts) with estrogen-receptor-positive (ER+), HER2-negative MBC, yet resistance ultimately develops. We hav...

Keywords:

Hydroxychloroquine
Metastatic breast cancer
Efficacy Study
Autophagy
Estrogen receptor
Augment
Oncology
Letrozole
Medicine
Internal medicine
Palbociclib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations